What happened with SCTX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Scribe Therapeutics is developing medicines that act on genes inside the body, with its own pipeline focused on lowering blood lipids linked to cardiovascular disease. Its ELXR technology is designed to suppress gene activity without changing the DNA sequence, while XE edits DNA. Its lead candidate, STX-1150, uses ELXR to seek long-lasting reductions in LDL cholesterol and has entered a first-in-human trial in Australia; STX-1200 and STX-1400 remain in preclinical development.
Pharmaceutical partners pay Scribe for access to its technology and research work, rather than patients paying for approved medicines. Lilly’s subsidiary Prevail licenses technology for neurological and neuromuscular diseases, while Sanofi collaborates on sickle cell and other genetic diseases. These relationships account for essentially all revenue, with Prevail supplying most. Payments include upfront fees, research funding and milestones; future royalties depend on licensed medicines reaching the market. Continued receipts depend on partners advancing programs and meeting agreed targets.
Scribe has no approved products and has never generated product-sales revenue. Selling a medicine in the United States requires FDA approval supported by clinical evidence. The company also needs substantial additional capital to complete development: its existing resources and offering proceeds are not enough to take any program through regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Scribe's prospects also hinge on turning its platforms into safe, durable medicines using delivery technology licensed from Acuitas.
Lilly both funds Scribe and competes with it: its Prevail subsidiary pays to use Scribe's editing technology and research services, while Verve develops rival PCSK9 and Lp(a) editing medicines. Prevail supplied all of Scribe's collaboration revenue in the three months ended March 31, 2026, making that research relationship especially important to near-term revenue.
Editas Medicine competes with Scribe to develop medicines that edit genes inside the body for high blood lipids and inherited hemoglobin disorders. Progress in Editas's EDIT-401 cardiovascular candidate and sickle cell programs is worth watching alongside Scribe's lipid-editing pipeline and Sanofi collaboration.
CRISPR Therapeutics competes with Scribe in gene-editing medicines aimed at lowering lipoprotein(a), or Lp(a). Its Lp(a) program's safety and effectiveness will help frame the competitive bar for Scribe's STX-1200, which edits LPA in liver cells.
Sanofi pays Scribe to use its editing technologies for sickle cell disease and other targets, tying Scribe's potential milestone and royalty income to Sanofi's drug development. Watch the additional target covered by the July 2026 amendment, which extended Sanofi's selection period and added Scribe's ELXR platform for that target.
Metagenomi Therapeutics competes with Scribe's STX-1400 on editing APOC3 for potentially durable triglyceride reduction, with Ionis funding its partnered research. Metagenomi's APOC3 program was in lead optimization in 2025; watch whether it advances toward demonstrating the lasting benefit Scribe also seeks.
Intellia Therapeutics offers clinical benchmarks for Scribe's liver-directed editing medicines, though they target different diseases and Scribe's platforms had not been clinically tested. Safety, durability and regulatory progress in Intellia's Phase 3 lonvo-z and nex-z programs are the signals to watch.
Beam Therapeutics' advances and setbacks in editing genes inside the body inform the delivery and safety challenges facing Scribe, although Beam changes individual DNA bases while Scribe uses CasX-based editors. Beam's partnered work on in vivo editing for rare genetic diseases is a useful place to watch for effective delivery and lasting effects.
Ionis Pharmaceuticals already sells the APOC3-lowering medicine TRYNGOLZA, setting an existing treatment benchmark for Scribe's STX-1400. Watch TRYNGOLZA's use in familial chylomicronemia syndrome as Scribe seeks to prove that APOC3 editing can deliver durable benefits rather than require chronic treatment.
Alnylam's licensed medicine Leqvio already targets PCSK9, competing with the LDL-C-lowering approach Scribe is developing through STX-1150. MDCO holds Leqvio's global rights, so its effectiveness, safety and convenience are the treatment benchmarks to watch rather than Alnylam's own product sales.
Prime Medicine and Scribe both need to deliver gene editors safely and effectively into liver cells, although Prime treats liver diseases and Scribe targets cardiometabolic risk. Prime's in vivo Wilson disease and alpha-1 antitrypsin deficiency programs are the relevant delivery and durability readouts, rather than its cell-editing work outside the body.
Ionis Pharmaceuticals, Inc. earningsIONS
Ionis’s report can show whether its marketed APOC3-lowering medicine TRYNGOLZA is gaining use, a demand and access benchmark for Scribe’s STX-1400.
Watch changes in TRYNGOLZA use and sales. Growth would show real demand for APOC3-lowering treatment, but would not mean patients will choose an unproven gene-editing approach; weak use would show that adoption and coverage cannot be taken for granted. Scribe still has to show that STX-1400 can deliver lasting benefit that patients and payers accept.
Intellia Therapeutics, Inc earningsNTLA
Intellia’s clinical progress can show how liver-directed editing is faring on safety and durability in people, a reference point for Scribe’s untested platforms.
Watch safety, durability of effect, and regulatory progress in Intellia’s clinical programs. Continued progress on those fronts would show that in vivo editing can move toward lasting treatment in people; safety problems or delays would bring the delivery and safety hurdles into sharper view. Intellia uses a different editing technology, so its results are a field benchmark, not proof of Scribe’s efficacy.
CRISPR Therapeutics AG earningsCRSP
CRISPR Therapeutics’ report can show how its Lp(a) editing program is progressing, a direct competitive reference for Scribe’s STX-1200.
Watch whether CRISPR Therapeutics’ Lp(a) program advances clinically and what it reports about safety and effect. Clear progress with acceptable safety would make a rival approach more credible and raise the bar for STX-1200; delays or safety problems would ease immediate competitive pressure, but Scribe would still have to prove its own candidate works safely.
Scribe Therapeutics Inc. earningsThis company
Scribe Therapeutics relies on collaboration and license income to fund research, and this report will show whether that income is keeping pace with development spending.
Read collaboration revenue alongside operating expenses and cash use. Higher revenue with controlled expenses and cash use means partners are covering more of the research bill; lower revenue without a matching drop in spending widens the gap and leaves Scribe more reliant on outside funding. Milestone payments can make collaboration revenue lumpy, so a one-quarter increase does not by itself show that income is steady.
